Social and Emotional Development Support Program for Adolescents: Effects on Belonging, Meaning in Life, Authenticity, Well-Being, and Resilience (SEDESP)

March 4, 2026 updated by: Didem Aslanyürek, Hacettepe University

An Examination of the Effects of the Social and Emotional Development Support Program on Adolescents' Sense of Belonging, Meaning in Life, Emotional Authenticity, Well-Being, and Psychological Resilience

This study aims to examine the effectiveness of the Social and Emotional Developmental Support Program on adolescents' sense of belonging, meaning in life, emotional authenticity, well-being, and resilience. The study will be conducted with 9th-grade students studying in Defne district of Hatay, Türkiye, one of the regions affected by the Kahramanmaraş-centered earthquake that occurred on February 6, 2023. A pre-test/post-test control group experimental design will be used to evaluate the effectiveness of the program.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study aims to examine the effects of the Social and Emotional Developmental Support Program, which will be implemented with ninth-grade students studying in the Defne district of Hatay, on adolescents' sense of belonging, meaning in life, emotional authenticity, well-being, and resilience. The research will be carried out with adolescents living in Defne, one of the districts of Hatay most affected by the Kahramanmaraş-centered earthquake that occurred in Türkiye on February 6, 2023. The study is designed as a pre-test/post-test control group experimental design. Participants will be randomly assigned to experimental and control groups. The experimental group will receive the Social and Emotional Developmental Support Program, whereas no intervention will be provided to the control group during the study period. Data will be collected using a demographic information form and standardized instruments assessing adolescents' sense of belonging, meaning in life, emotional authenticity, well-being, and resilience. The findings are expected to contribute to the social and emotional development of adolescents affected by the earthquake and to enrich the existing body of literature.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Turkey (Türkiye)
    • Defne
      • Hatay, Defne, Turkey (Türkiye), 31160
        • Defne Public High Schools

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Adolescents aged between 14 and 15 years
  • Ninth-grade students enrolled in public high schools located in the Defne district of Hatay
  • Individuals who resided in the Defne district on February 6, 2023
  • Students who voluntarily agree to participate and whose parental consent has been obtained
  • Students who are able to attend all program sessions regularly

Exclusion Criteria:

  • Students who did not reside in the Defne district on February 6, 2023
  • Students with special educational needs or those reported by school counselors or parents to have developmental or psychiatric diagnoses
  • Students who are simultaneously participating in another psychosocial intervention program
  • Students with cognitive limitations that prevent them from completing the study assessments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Social and Emotional Developmental Support Program
Participants in this group will receive the Social and Emotional Developmental Support Program, which aims to enhance adolescents' sense of belonging, meaning in life, emotional authenticity, well-being, and resilience. The program will be implemented over several structured sessions conducted in a school setting.
Behavioral: Social and Emotional Developmental Support Program
A structured program designed to promote adolescents' social and emotional development. The program includes interactive sessions aimed at enhancing belonging, meaning in life, emotional authenticity, well-being, and resilience. It will be implemented in a school setting through group-based activities and reflective discussions.
No Intervention: No Intervention (Assessment Only Control Group)
Participants in this group will not receive any intervention during the study period. They will complete the same pre- and post-test assessments as the experimental group.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
The General Belongingness Scale
Time Frame: Baseline (pre-test) and after completion of the intervention (approximately 11 weeks).
Participants' sense of belonging will be assessed using the General Belongingness Scale. The General Belongingness Scale is answered on a four-point Likert scale with the options "(1) Strongly disagree, (2) Somewhat disagree, (3) Mostly agree, (4) Strongly agree." Six items represent the rejection/exclusion dimension, while the remaining six items reflect the acceptance/inclusion dimension. When all 12 items are evaluated together, a total belongingness score is obtained. In this context, higher total scores indicate higher levels of general belongingness among adolescents.
Baseline (pre-test) and after completion of the intervention (approximately 11 weeks).
Meaning in Life Questionnaire
Time Frame: Baseline (pre-test) and after completion of the intervention (approximately 11 weeks).
Participants' perceived meaning in life will be assessed using the Meaning in Life Questionnaire. Higher scores on the Presence of Meaning subscale indicate that individuals perceive their lives as more meaningful and purposeful, whereas higher scores on the Search for Meaning subscale reflect greater efforts to find or develop meaning in life. When calculating the total score by reverse-coding the Search subscale, a higher overall score signifies a stronger sense of meaning in life.
Baseline (pre-test) and after completion of the intervention (approximately 11 weeks).
Emotional Authenticity Scale
Time Frame: Baseline (pre-test) and after completion of the intervention (approximately 11 weeks).
Participants' emotional authenticity will be measured using the Emotional Authenticity Scale. The Emotional Authenticity Scale is a 20-item self-report measure assessing the extent to which individuals express their emotions in a genuine, coherent, and self-consistent manner. Items are rated on a 1-5 Likert scale. Five items from the "Acceptance of External Influence" subscale and seven items from the "Emotional Avoidance" subscale are reverse-scored. Higher total scores indicate greater emotional authenticity.
Baseline (pre-test) and after completion of the intervention (approximately 11 weeks).
EPOCH Well-being Scale
Time Frame: Baseline (pre-test) and after completion of the intervention (approximately 11 weeks).
Participants' well-being levels will be assessed using the EPOCH Well-Being Measure. The scale consists of five subscales and a total of 20 items. Higher scores on each subscale indicate a greater level of the specific characteristic assessed by that dimension. In addition, the scale provides an overall well-being score. During scoring, mean scores are calculated for each subscale as well as for the total scale.
Baseline (pre-test) and after completion of the intervention (approximately 11 weeks).
Psychological Resilience Attitude and Skills Scale
Time Frame: Baseline (pre-test) and after completion of the intervention (approximately 11 weeks).
Participants' resilience levels will be measured using the Resilience Attitude and Skill Scale. It is a 34-item, single-factor measurement tool rated on a four-point Likert scale. There are no reverse-scored items in the scale. Higher scores indicate higher levels of psychological resilience.
Baseline (pre-test) and after completion of the intervention (approximately 11 weeks).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hacettepe University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 8, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 26, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 19, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 19, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 28, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 5, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 4, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • DIDEM-ASLANYUREK-INTERV-2025
  • E-68552689-302.08-00003594733 (Other Identifier: Hacettepe University Social and Human Sciences Research Ethics Committee)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The individual participant data will not be shared due to ethical considerations and confidentiality requirements. The dataset includes sensitive information from adolescent participants collected in a school setting, and sharing such data could compromise participant privacy. The data will not be shared with third parties except for scientific purposes within the approved research framework.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings